261 related articles for article (PubMed ID: 34157136)
81. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
82. Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-α deficiency.
Resaz R; Vanni C; Segalerba D; Sementa AR; Mastracci L; Grillo F; Murgia D; Bosco MC; Chou JY; Barbieri O; Varesio L; Eva A
Dis Model Mech; 2014 Sep; 7(9):1083-91. PubMed ID: 25147298
[TBL] [Abstract][Full Text] [Related]
83. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
Luo X; Hall G; Li S; Bird A; Lavin PJ; Winn MP; Kemper AR; Brown TT; Koeberl DD
Mol Ther; 2011 Nov; 19(11):1961-70. PubMed ID: 21730973
[TBL] [Abstract][Full Text] [Related]
84. Vaccinia Virus Genome Editing Using CRISPR.
Di Gioia C; Yuan M; Wang Y
Methods Mol Biol; 2019; 2023():109-117. PubMed ID: 31240673
[TBL] [Abstract][Full Text] [Related]
85. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
86. Cloning and characterization of cDNAs encoding a candidate glycogen storage disease type 1b protein in rodents.
Lin B; Annabi B; Hiraiwa H; Pan CJ; Chou JY
J Biol Chem; 1998 Nov; 273(48):31656-60. PubMed ID: 9822626
[TBL] [Abstract][Full Text] [Related]
87. Regulation of hepatic gluconeogenesis by nuclear factor Y transcription factor in mice.
Zhang Y; Guan Q; Liu Y; Zhang Y; Chen Y; Chen J; Liu Y; Su Z
J Biol Chem; 2018 May; 293(20):7894-7904. PubMed ID: 29530977
[TBL] [Abstract][Full Text] [Related]
88. Gene editing in clinical isolates of Candida parapsilosis using CRISPR/Cas9.
Lombardi L; Turner SA; Zhao F; Butler G
Sci Rep; 2017 Aug; 7(1):8051. PubMed ID: 28808289
[TBL] [Abstract][Full Text] [Related]
89. CRISPR/Cas gene therapy.
Zhang B
J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
[TBL] [Abstract][Full Text] [Related]
90. Directed Evolution of CRISPR-Cas9 Base Editors.
Winter J; Perez-Pinera P
Trends Biotechnol; 2019 Nov; 37(11):1151-1153. PubMed ID: 31623959
[TBL] [Abstract][Full Text] [Related]
91. Glycogen storage disease type 1a in Israel: biochemical, clinical, and mutational studies.
Parvari R; Lei KJ; Bashan N; Hershkovitz E; Korman SH; Barash V; Lerman-Sagie T; Mandel H; Chou JY; Moses SW
Am J Med Genet; 1997 Oct; 72(3):286-90. PubMed ID: 9332655
[TBL] [Abstract][Full Text] [Related]
92. Rapid interrogation of cancer cell of origin through CRISPR editing.
Feng W; Cao Z; Lim PX; Zhao H; Luo H; Mao N; Lee YS; Rivera AA; Choi D; Wu C; Han T; Romero R; de Stanchina E; Carver BS; Wang Q; Jasin M; Sawyers CL
Proc Natl Acad Sci U S A; 2021 Aug; 118(32):. PubMed ID: 34353917
[TBL] [Abstract][Full Text] [Related]
93. Heterogeneous mutations in the glucose-6-phosphatase gene in Japanese patients with glycogen storage disease type Ia.
Takahashi K; Akanuma J; Matsubara Y; Fujii K; Kure S; Suzuki Y; Wataya K; Sakamoto O; Aoki Y; Ogasawara M; Ohura T; Miyabayashi S; Narisawa K
Am J Med Genet; 2000 May; 92(2):90-4. PubMed ID: 10797430
[TBL] [Abstract][Full Text] [Related]
94. Fgf10-CRISPR mosaic mutants demonstrate the gene dose-related loss of the accessory lobe and decrease in the number of alveolar type 2 epithelial cells in mouse lung.
Habuta M; Yasue A; Suzuki KT; Fujita H; Sato K; Kono H; Takayama A; Bando T; Miyaishi S; Oyadomari S; Tanaka E; Ohuchi H
PLoS One; 2020; 15(10):e0240333. PubMed ID: 33057360
[TBL] [Abstract][Full Text] [Related]
95. CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver.
Kaltenbacher T; Löprich J; Maresch R; Weber J; Müller S; Oellinger R; Groß N; Griger J; de Andrade Krätzig N; Avramopoulos P; Ramanujam D; Brummer S; Widholz SA; Bärthel S; Falcomatà C; Pfaus A; Alnatsha A; Mayerle J; Schmidt-Supprian M; Reichert M; Schneider G; Ehmer U; Braun CJ; Saur D; Engelhardt S; Rad R
Nat Protoc; 2022 Apr; 17(4):1142-1188. PubMed ID: 35288718
[TBL] [Abstract][Full Text] [Related]
96. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics.
Kishnani PS; Austin SL; Abdenur JE; Arn P; Bali DS; Boney A; Chung WK; Dagli AI; Dale D; Koeberl D; Somers MJ; Wechsler SB; Weinstein DA; Wolfsdorf JI; Watson MS;
Genet Med; 2014 Nov; 16(11):e1. PubMed ID: 25356975
[TBL] [Abstract][Full Text] [Related]
97. Modifiable factors affecting renal preservation in type I glycogen storage disease after liver transplantation: a single-center propensity-match cohort study.
Chan YC; Liu KM; Chen CL; Ong AD; Lin CC; Yong CC; Tsai PC; Lu LS; Wu JY
Orphanet J Rare Dis; 2021 Oct; 16(1):423. PubMed ID: 34635148
[TBL] [Abstract][Full Text] [Related]
98. Characterization of liver GSD IX γ2 pathophysiology in a novel Phkg2
Gibson RA; Lim JA; Choi SJ; Flores L; Clinton L; Bali D; Young S; Asokan A; Sun B; Kishnani PS
Mol Genet Metab; 2021 Jul; 133(3):269-276. PubMed ID: 34083142
[TBL] [Abstract][Full Text] [Related]
99. Molecular, Biochemical, and Clinical Characterization of Thirteen Patients with Glycogen Storage Disease 1a in Malaysia.
Abdul Wahab SA; Yakob Y; Mohd Khalid MKN; Ali N; Leong HY; Ngu LH
Genet Res (Camb); 2022; 2022():5870092. PubMed ID: 36160031
[TBL] [Abstract][Full Text] [Related]
100. Gene therapy for glycogen storage diseases.
Koeberl DD; Koch RL; Lim JA; Brooks ED; Arnson BD; Sun B; Kishnani PS
J Inherit Metab Dis; 2024 Jan; 47(1):93-118. PubMed ID: 37421310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
